Trials / Completed
CompletedNCT02738138
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
Conditions
- Hepatitis C Virus Infection
- Human Immunodeficiency Virus Infection
- Chronic Hepatitis C
- Compensated Cirrhosis and Non-cirrhotics
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493 coformulated with ABT-530 | Tablet |
Timeline
- Start date
- 2016-05-17
- Primary completion
- 2017-03-15
- Completion
- 2017-06-07
- First posted
- 2016-04-14
- Last updated
- 2021-07-13
- Results posted
- 2018-05-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02738138. Inclusion in this directory is not an endorsement.